In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lion Biotechnologies licenses tumor cell therapy technologies from Moffitt Cancer Center

Executive Summary

Lion Biotechnologies Inc. (cancer immunotherapies) licensed exclusive rights to two patent-pending tumor infiltrating lymphocyte (TIL) technologies from the University of South Florida’s H. Lee Moffitt Cancer Center & Research Institute. The license continues until the last patent related to the technologies expires, or 20 years, whichever comes first.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies